180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD.
Stocks found in the category TradersPro New Uptrend are low priced stocks priced between .30 and $3, with at least 50k shares of average shares trading per day. The stocks are starting new uptrends and have buy signals. These are high reward to risk stocks with the potential for very sharp moves. A stop should be maintained at the low of the most recent hold signal day. Target prices for exits can be determined by using the next level of resistance higher or by using Fibonacci resistance levels found using TradersPro. Trailing stops or letting the stock run until the next sell signal is also a sell strategy.